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Erythropoiesis-stimulating agents (ESAs) are effective in
ameliorating anemia in chronic kidney disease (CKD). A
recent trial in diabetic patients with CKD, however, suggested
a greater risk of stroke associated with full correction of
anemia with ESAs. Using national Veterans Affairs data we
performed a case–control study examining the association of
incident ESA use with acute stroke in patients with estimated
glomerular filtration rate o60cm3/min per 1.73m2 and
outpatient hemoglobin o12g/dl. Using diagnosis codes, we
identified 2071 acute hospitalized stroke cases and matched
them 1:5 with controls without stroke, resulting in 12,426
total patients for analysis. Conditional logistic regression was
used to estimate the association of ESA use with stroke,
adjusting for potential confounders. After multivariate
adjustment, ESA use in 1026 patients was associated with
greater odds of stroke (odds ratio 1.30). There was significant
interaction between ESA use and cancer, with greater odds of
stroke among ESA-treated cancer patients (odds ratio 1.85),
but not in ESA-treated patients without cancer (odds ratio
1.07). ESA-treated patients with cancer received a median
initial dose 2.5–4 times greater than ESA-treated patients
without cancer, but pre-ESA hemoglobin and its rate of
change did not differ between these groups. Hence, in a
large national sample of anemic patients with CKD, ESA
treatment was associated with an increased risk of acute
stroke with the greatest effect among patients with cancer.
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Anemia is a common complication of non-dialysis-depen-
dent chronic kidney disease (CKD) and is associated with an
increased risk of morbidity and mortality, including acute
stroke.1–5 Consensus-based guidelines endorse the use of
erythropoiesis-stimulating agents (ESAs) for the treatment of
CKD-related anemia.6 ESAs have been established as an
effective treatment for raising hemoglobin (Hb) concentra-
tion,7 reducing the need for red blood cell transfusions,6 and
improving anemia symptoms.8
However, recent clinical trials of ESAs in CKD have raised
concerns about potential cardiovascular risks. The TREAT
study in anemic non-dialysis diabetic CKD patients reported
an excess risk of stroke with ESA use dosed for a target Hb of
13 g/dl, compared to limited ESA use to maintain HbX9 g/dl.9
The CHOIR and CREATE studies, which compared the
effects of using ESAs to achieve a high Hb goal versus a
standard goal in non-dialysis CKD patients, found no excess
risk of stroke, although there were few total strokes in either
study.10,11 However, the CHOIR trial did find an excess of
cardiovascular morbidity10 and the CREATE trial an excess of
end-stage renal disease11 in the higher Hb target groups.
These findings have raised concerns regarding the relative
benefits and risks of ESA treatment to correct anemia in
patients with CKD. In reaction to these findings from clinical
trials, the Food and Drug Administration issued a ‘black-box
warning’ for darbepoetin alfa and epoetin alfa in 2007
recommending physicians to prescribe the lowest possible
dose to gradually raise the Hb concentration to the lowest
level necessary to avoid the need for a blood transfusion.12–14
These findings suggest that for some anemic CKD patients,
the potential risks associated with ESA use may outweigh the
benefits, especially with regards to stroke. However, the factors
that may account for the excess risk of stroke are unclear.
Furthermore, the risks observed with ESA treatment among a
carefully selected patient sample included in a randomized
clinical trial may not be generalizable to a ‘real-world’
ambulatory clinical-care setting. For example, prior ESA trials
in non-dialysis CKD have excluded patients with cancer or
recent cardiovascular events.9–11 Therefore, we conducted an
observational nested case–control study to examine the
relationship of ESA use with acute stroke in anemic non-
dialysis CKD patients and among subgroups of patients with
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comorbidities including diabetes and cancer, using national
data from the Veterans Health Administration (VHA).
RESULTS
Study sample
A total of 2071 stroke cases were among the anemic CKD
patients who met inclusion criteria. After 5:1 matching of
controls, there were 12,426 total patients for analysis.
Table 1 lists the characteristics of the cases and controls.
Compared with controls, stroke cases were more likely to be
African American and had a greater prevalence of diabetes,
congestive heart failure, myocardial infarction, coronary
artery disease (CAD), hypertension, atrial fibrillation,
transient ischemic attack (TIA), and prior stroke. In addition,
Table 1 | Characteristics of stroke cases and controls, and ESA users and non-users
No stroke (controls) Stroke (cases) P-value No ESA use ESA use P-value
Sample size N=10,355 N=2071 N=11,400 N=1026
Demographics
Age, years 73.77 (10.44) 72.38 (10.36) o0.001 73.80 (10.35) 70.66 (11.01) o0.001
Sex 0.6 0.5
Male 10,050 (97.1%) 2015 (97.3%) 11,065 (97.1%) 1000 (97.5%)
Female 305 (2.9%) 56 (2.7%) 335 (2.9%) 26 (2.5%)
Race o0.001
Caucasian 8527 (82.3%) 1449 (70%) 9205 (80.7%) 771 (75.1%) o0.001
African American 1732 (16.7%) 605 (29.2%) 2095 (18.4%) 242 (23.6%)
Other 96 (0.93%) 17 (0.82%) 100 (0.9%) 13 (1.3%)
Key dates
Cohort year of incident CKD 1.0 0.2
1 April 2000 to 31 March 2001 7355 (71%) 1471 (71%) 8074 (70.8%) 752 (73.3%)
1 April 2002 to 31 March 2003 2275 (22%) 455 (22%) 2517 (22.1%) 213 (20.8%)
1 April 2004 to 31 March 2005 725 (7%) 145 (7%) 809 (7.1%) 61 (5.9%)
Days from anemiaa 455.92 (449.04) 463.42 (445.89) 0.5 444.26 (443.97) 600.59 (473.22) o0.001
eGFR
Lowest eGFR, cm3/min per 1.73m2
b
41.88 (19.32) 40.48 (18.32) 0.007 38.37 (13.54) 26.94 (16.29) o0.001
First eGFR, cm3/min per 1.73m2
b
50.10 (20.72) 50.26 (19.70) 0.7 48.35 (11.12) 42.75 (15.11) o0.001
Most recent eGFR, cm3/min per 1.73m2
b
50.03 (23.23) 50.88 (23.0) 0.14 51.34 (22.14) 39.12 (27.66) o0.001
Hb
First Hb, g/dlc 10.85 (1.26) 10.90 (1.14) 0.09 10.89 (1.23) 10.49 (1.32) o0.001
Most recent Hb, g/dlc 11.42 (1.78) 11.65 (1.77) o0.001 11.57 (1.74) 10.20 (1.67) o0.001
Blood transfusion prior to study index date 2030 (19.6%) 423 (20.4%) 0.4 2122 (18.6%) 331 (32.3%) o0.001
Processes of care (prior clinic visits)
Chemotherapy 365 (3.5%) 52 (2.5%) 0.02 280 (2.5%) 137 (13.4%) o0.001
Internal medicine 3936 (38.0%) 914 (44.1%) o0.001 4172 (36.6%) 678 (66.1%) o0.001
Primary care 7564 (73.0%) 1560 (75.3%) 0.03 8454 (74.2%) 670 (65.3%) o0.001
Nephrology 601 (5.8%) 202 (9.8%) o0.001 538 (4.7%) 265 (25.8%) o0.001
Number of prior hospitalizations o0.001 0.5
0 4124 (39.8%) 627 (30.3%) 4373 (38.4%) 378 (36.8%)
1 2371 (22.9%) 566 (27.3%) 2688 (23.6%) 249 (24.3%)
2 1512 (14.6%) 322 (15.5%) 1668 (14.6%) 166 (16.2%)
3 or more 2348 (22.7%) 556 (26.8%) 2671 (23.4%) 233 (22.7%)
Comorbidities
Cancerd 1230 (11.9%) 175 (8.5%) o0.001 1009 (9.6%) 306 (29.8%) o0.001
Diabetes 4745 (45.8%) 1136 (54.9%) o0.001 5341 (46.9%) 540 (52.6%) o0.001
Hypertension 8863 (85.6%) 1933 (93.3%) o0.001 9909 (86.9%) 887 (86.5%) 0.7
Atrial fibrillation 2170 (21.0%) 516 (24.9%) 0.4 2522 (22.1%) 164 (16.0%) o0.001
CAD and/or MI 5686 (54.9%) 1231 (59.4%) o0.001 6422 (56.3%) 495 (48.2%) o0.001
Prior TIA 555 (5.4%) 509 (24.6%) o0.001 1022 (9.0%) 42 (4.1%) o0.001
GI bleed 836 (8.1%) 231 (11.2%) o0.001 983 (8.6%) 84 (8.2%) 0.6
Prior stroke 1027 (9.9%) 688 (33.2%) o0.001 1640 (14.4%) 75 (7.3%) o0.001
Abbreviations: CAD, coronary artery disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agent; GI, gastrointestinal;
Hb, hemoglobin; MI, myocardial infarction; TIA, transient ischemic attack.
Values are given as n (%) or mean (s.d.) as appropriate.
aDays from anemia index date to study index date (days).
bIncluding outpatient eGFR measures from CKD index date to study index date, inclusive.
cIncluding Hb measurements from anemia index date to study index date (for non-ESA users) or to date of ESA initiation date (for ESA users).
dDiagnosis code for malignancy (excluding non-melanoma skin cancers), andX1 hematology/oncology visit within 6 months prior to date of first ESA use (for ESA users) or
study index date (for non-ESA users).
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the cases were nearly twice as likely to have visited a
nephrologist within 6 months prior to the index anemia date
as compared with the controls. The mean qualifying
estimated glomerular filtration rate (eGFR) and Hb values
among cases and controls did not differ significantly.
ESA use
A total of 1026 patients were prescribed outpatient ESAs.
Compared with the group of patients that did not use
ESAs (Table 1), the patients prescribed ESAs were more
likely to be African American, and were more likely to have
cancer and diabetes. These patients were also more likely
to have had chemotherapy and visits to hematology/
oncology, internal medicine, and nephrology clinics within
6 months prior to the index anemia date. Compared with
the non-ESA-treated patients, these patients also had a lower
eGFR and Hb, and were twice as likely to have received
prior blood transfusions. In contrast, ESA-treated patients
were less likely to have atrial fibrillation, CAD, and prior
stroke or TIA.
Primary results
The association of ESA use with stroke case status before
and after multivariate adjustment is shown in Table 2.
In unadjusted and demographic-adjusted models, no asso-
ciation was observed between ESA use and stroke status.
However, after adjustment for comorbidity, a trend toward
greater odds of stroke with prior ESA use was observed
(adjusted odds ratio (aOR)¼ 1.19, P¼ 0.07). Examination of
the confounding effects of individual covariates suggested
two covariates were most influential: (1) cancer with active
oncology care, which was more frequent in ESA users but
associated with a lower odds (aOR¼ 0.77) of stroke, and (2)
prior cerebrovascular disease, which was less frequent in ESA
users and also associated with an approximately fourfold risk
(aOR¼ 3.97) of acute stroke. In the full multivariate model,
ESA use was associated with a 30% greater odds of stroke
(aOR¼ 1.30, 95% CI¼ 1.06, 1.58) after additional adjust-
ment for eGFR, Hb, and healthcare utilization. In a secondary
analysis, those with initial ESA dose below the median
(o100 mcg/week darbepoetin or o10,000 U/week epoetin
alfa) had a 24% greater odds of stroke (aOR¼ 1.24, 95%
CI¼ 0.90, 1.70) and those with initial ESA dose greater than
or equal to the median had a 33% greater odds of stroke
(aOR¼ 1.33, 95% CI¼ 1.05, 1.67).
Effect modification
Differences in odds ratios for ESA and stroke were further
examined in several pre-defined comorbidity subgroups:
including cancer, diabetes, cerebrovascular disease (prior TIA
and/or stroke), CAD, prior nephrology care, and prior atrial
fibrillation. Each interaction was examined separately, and
the results are shown in Table 3. There was a significant effect
modification (P¼ 0.015) by cancer under active oncology
care. Model-based strata-specific odds ratio estimates show
that, among patients with cancer, ESA use was associated
with an 83% greater odds of stroke (OR¼ 1.83), whereas no
significant association was observed among patients without
cancer (OR¼ 1.07).
Additional exploratory analyses were conducted to
examine factors that might explain this effect modification
by cancer. We stratified patients by type of ESA, and
examined ESA dosing, pre-ESA anemia severity, and response
of Hb to therapy. Among epoetin users (N¼ 887; Figure 1),
Table 2 | Association of ESA use with stroke case status, before and after multivariate adjustment
Unadjusted
odds ratio
Adjusted for
demographicsa
+Adjusted for
comorbidityb
+Adjusted for
eGFR and Hbc
+Adjusted for processes of
care and hospitalizationd
Odds ratio (95% CI)
ESA use 1.05 (0.89, 1.25) 0.97 (0.81, 1.15) 1.19 (0.99, 1.42) 1.38 (1.14, 1.68) 1.30 (1.06, 1.58)
P=0.5 P=0.7 P=0.07 P=0.001 P=0.01
Abbreviations: CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agent; Hb, hemoglobin; MI, myocardial infarction;
TIA, transient ischemic attack.
aDemographic covariates: age, race.
bDiabetes, CAD (including h/o MI), cancer under active oncological care, prior stroke/cerebrovascular disease, atrial fibrillation, and prior TIA.
cHb on index anemia date (first Hb o12 g/dl), difference between latest and first Hb, lowest eGFR, difference between latest and first eGFR, including measurements
performed prior to study index date (for non-ESA users) or on or before initial ESA prescription (for ESA users).
dNephrology, internal medicine, and chemotherapy clinic visits, and hospitalization rate per month.
Table 3 | Odds ratios for ESA and stroke among comorbidity
subgroups
Odds ratio (95% CI) P-value for interaction
No cancer 1.07 (0.85, 1.34)
0.015
Cancer 1.83 (1.26, 2.65)
No diabetes 1.20 (0.93, 1.55)
0.8
Diabetes 1.25 (0.94, 1.65)
No prior stroke/TIA 1.41 (1.14, 1.75)
0.02
Prior stroke/TIA 0.76 (0.50, 1.24)
No CAD 1.29 (0.99, 1.69)
0.5
CAD 1.15 (0.88, 1.50)
No nephrology carea 1.21 (0.96, 1.54)
0.3
Nephrology carea 1.53 (1.06, 2.21)
No atrial fibrillation 1.44 (1.16, 1.78)
0.02
Atrial fibrillation 0.80 (0.49, 1.28)
Abbreviations: CAD, coronary artery disease; ESA, erythropoiesis-stimulating agent;
TIA, transient ischemic attack.
Odds ratios estimated from conditional logistic models with multiplicative
(ESA co-morbidity) interaction terms.
aOutpatient nephrology clinic visit within 6 months prior to initiation of ESA use or
study index date (for patients not on ESA).
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cancer patients were prescribed a much higher initial dosage
of the ESA (median 40,000 versus 10,000 U/week in non-
cancer patients; Po0.001), although pre-ESA Hb was similar
(mean 10.0 versus 10.2 g/dl). Pre-ESA outpatient eGFR was
significantly higher in cancer patients versus non-cancer
patients (median (inter-quartile range): 56 (36–69) versus
25.4 (12.4–45) cm3/min per 1.73 m2, Po0.001). Among those
with sufficient post-ESA Hb measurements to calculate the
slope (75%), there was no statistical or clinically significant
difference in the rate of Hb rise between epoetin-treated
patients with cancer (median¼ 0.32 g/dl per month) versus
without cancer (0.18 g/dl per month; P¼ 0.2).
Among darbepoetin users (N¼ 139; Figure 2), the
results were similar, with a median dose of 100 mg/week in
cancer patients versus 40 mg/week in non-cancer patients
(Po0.001). Pre-ESA Hb and the slope of Hb after ESA
initiation did not differ significantly between the groups
(cancer: 0.43 g/dl per month, non-cancer: 0.22 g/dl per
month, P¼ 0.06), whereas pre-ESA outpatient eGFR was
significantly higher in the cancer patients (58.7 (47.6–77.8)
versus 29.3 (16.2–45.7) cm3/min per 1.73 m2, Po0.001).
Interaction was also noted between ESA use and a prior
stroke and/or TIA, with a 41% greater odds of acute stroke
among those without a prior stroke and/or TIA (Table 3). In
exploratory analyses, ESA-treated patients with prior stroke
and/or TIA compared with ESA-treated patients without
prior stroke and/or TIA had higher mean pretreatment
Hb (mean (s.d.): 10.7 (1.7) versus 10.1 (1.7) g/dl, P¼ 0.003),
lower initial doses of epoetin alfa (median (inter-quartile
range): 10,000 (4000–20,000) versus 10,000 (8000–40,000)
U/week; P¼ 0.001), and similar increases in Hb in the
6 months after ESA initiation (0.7 (2.9) versus 0.5 (2.1) g/dl
per month, P¼ 0.5). There was a significant interaction
between ESA use and a prior diagnosis of atrial fibrillation
(P¼ 0.02; Table 3), with a greater odds of stroke in ESA users
only among those without an assigned diagnosis of atrial
fibrillation. There was no significant interaction between ESA
use and prior nephrology care, CAD, or diabetes.
DISCUSSION
Among a large national case–control sample of CKD patients
with anemia, those treated with ESAs had a 30% greater odds
of stroke than patients who were not treated with ESAs, after
adjustment for multiple confounding variables including
demographics, comorbidity, severity and rate of progression
of anemia, and healthcare utilization. The increased risk of
stroke associated with ESA use was most pronounced among
patients with cancer.
Our findings are generally consistent with the results of
the TREAT study, which randomized diabetic CKD patients
to darbepoetin dosed to maintain Hb of 13 g/dl versus
placebo control with limited darbepoetin therapy to maintain
Hb X9 g/dl. Although there was no difference in mortal-
ity between the two groups, patients assigned to active
darbepoetin treatment had double the risk of stroke when
compared with those receiving placebo (153 total events, 5.0
versus 2.6%).9 Our results, in a large CKD sample with over
2000 stroke cases, generalize the TREAT study findings to a
more heterogeneous clinical population including non-
diabetics and patients with cancer. The CHOIR and CREATE
trials, which randomized anemic non-dialysis CKD patients
to high and low Hb targets, did not find an excess risk of
stroke with higher goal Hb.10,11 However, the number of
stroke events was very low in both trials, and none of the
three prior studies were specifically designed to examine
stroke as the primary outcome. Nonetheless, participants
assigned to a higher Hb target had a greater risk of end-stage
renal disease in the CREATE11 study and a greater risk of
cardiovascular events and mortality in CHOIR.10
We did not find evidence for a differential relation of ESA
use with stroke between those with and without diabetes or
cardiovascular disease. However, a notable finding in our
study was a significant (P¼ 0.015) effect modification by the
presence of cancer, with an 83% greater odds of stroke
associated with ESA use among patients with cancer under
active oncology care. Data from several studies have shown
that ESA use among patients with certain types of cancer is
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Figure 1 | Initial epoetin alfa dose and pre-ESA Hb among
epoetin alfa users with and without cancer. (a) First dose of
epoetin alfa among patients with and without cancer. (b) Hb prior
to epoetin alfa administration, among patients with and without
cancer. P-values represent Wilcoxon ranks-sum tests (a) and
independent samples t-test (b). ESA, erythropoiesis-stimulating
agent; Hb, hemoglobin.
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Figure 2 | Initial darbepoetin alfa dose and pre-ESA Hb among
darbepoetin alfa users with and without cancer. (a) First
dose of darbepoetin alfa among patients with and without cancer.
(b) Hb prior to darbepoetin alfa administration among patients
with and without cancer. P-values represent Wilcoxon
ranks-sum tests (a) and independent samples t-test (b). ESA,
erythropoiesis-stimulating agent; Hb, hemoglobin.
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associated with an increased risk of mortality and tumor
progression or recurrence.15–18 However, to our knowledge
this study is the first to report an association of excess stroke
risk with ESA use in CKD patients with cancer. Patients with
active cancer were excluded from the TREAT9 and CHOIR10
studies. To further investigate the reasons for this specific
effect modification, we examined factors related to anemia
and ESA use that differed between those with and without
cancer. We found that cancer patients were treated with much
higher initial doses of ESAs than non-cancer patients (2.5
times greater for darbepoetin users and 4 times greater for
epoetin users), although their severity of anemia prior to ESA
initiation did not differ. Furthermore, although there was a
large variation in the individual estimates of Hb change after
ESA initiation, overall we did not find marked differences
between CKD patients with and without cancer. These
findings of notably higher doses but similar hematopoietic
responses are consistent with a relative resistance among
cancer patients. The implications of such resistance on
vascular risk have been suggested recently in a re-analysis of
the TREAT study, in which a greater risk of cardiovascular
events was observed among those with a poorer hemato-
poietic response to initial doses of ESA.19 It is possible that
the greater association of ESA use with excess stroke in
patients with renal impairment and cancer in our study is
explained by their relatively greater ESA resistance.
Alternatively, the notably higher initial dosing of ESAs
in cancer patients may itself account for the greater
stroke risk associated with ESA use in this group of patients.
Results of our secondary analyses suggested a possible
dose–response relationship between ESA and odds of stroke,
at least based on initial dose. However, due to limitations
of the data sources, the specific dosing strategies and
treatment goals intended for these patients could not be
ascertained. Thus, our conclusions with regards to the
relative effects of ESA resistance and ESA dose on risk of
stroke are limited.
Furthermore, although all patients in the study sample
had eGFR o60 cm3/min per 1.73 m2 at the time of the onset
of anemia, many cancer patients at the time of ESA initiation
had only mild-to-moderately reduced eGFR or an eGFR
460 cm3/min per 1.73 m2, suggesting that relative erythro-
poietin deficiency may have contributed only modestly to
their anemia. In patients with malignancies, anemia may be
caused by multiple factors other than erythropoietin
deficiency, including inflammation, infection, blood loss,
bone marrow invasion, and effects of chemotherapy and/or
radiation therapy.20 These factors, in combination with the
generalized pro-coagulant state often present in malig-
nancy,21 may result in a greater susceptibility to any potential
pro-thrombotic effects of ESAs, resulting in an increased risk
of stroke in the setting of ESA treatment.
A nominally significant interaction was noted between
ESA use and prior stroke and/or TIA, with ESA use being
associated with an excess risk of new stroke only among those
without a documented prior stroke or TIA. The reasons for
this interaction are not entirely clear. ESA-treated patients
with prior stroke and/or TIA had less severe anemia, lower
initial doses of epoetin, and similar responses in Hb
compared to ESA-treated patients without prior stroke or
TIA. These results suggest that patients in this study sample
with prior cerebrovascular disease who were selected for ESA
treatment had greater hematopoietic response than their
counterparts without prior cerebrovascular disease, and this
selection may account for the observed interaction. An
interaction was also noted between ESA use and a prior
diagnosis of atrial fibrillation, with ESA use being associated
with stroke among those without prior atrial fibrillation but
not among those with this prior condition. This may
represent a chance finding in the setting of testing of
multiple interactions, or may relate to the different etiologies
of stroke in patients with atrial fibrillation compared with
those without this arrhythmia.
Limitations
There were several potential limitations in our study. The
case–control study design is inherently an observational one,
meaning that patients were not randomized to receive ESAs.
Patients with higher stroke risk may have been selected for
more frequent use and/or higher dosing of ESAs. Although
we did assess for the presence of malignancy and gastro-
intestinal bleeding—common causes of anemia in older
adults such as those patients in the study sample—the nature
of the data sources did not allow for precise ascertainment of
the specific biological causes of anemia for individual
patients. Since our study population consisted only of
patients within the VHA, our data may not be completely
applicable to other patient populations. For example, the
Veterans Affairs population is overwhelmingly male,
although there is no reason to believe that association
between ESA use and stroke differs between men and women.
The VHA population suffers from more chronic diseases than
the privately insured patient population,22 so results may not
necessarily be generalizable to patients with less comorbidity.
Patients in the study sample may have received medical
care—including oncological care—outside the VHA, which
would not be ascertained in our data and may have biased the
results. The study relied on administrative data collected over
several years, and has the potential for containing recording
errors and missing information, especially with regard to
chronic disease information. However, for the ascertainment
of acute stroke we used a validated coding algorithm that has
been previously shown to be highly accurate.23 In creating a
conditional logistic regression model to estimate the associa-
tion of ESA use with stroke, we adjusted for multiple
potential confounders. However, additional unmeasured
confounding variables may still be present and not accounted
for in the analysis.
Strengths
Despite the limitations inherent in a retrospective study, this
study represents a large national cohort of patients with CKD
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and anemia. The study population can thus be said to reflect
the real-world practices of VHA providers, at least at the time
of the study sample from 2001 through 2005. The large
number of stroke cases also permitted for evaluation of the
association of ESA use with stroke in clinically important
subgroups including non-diabetics, those with and with-
out CAD, and cancer. Since randomized controlled trials
generally enroll a selected population with lower morbidity
and mortality rates in comparison to the general population
with the disease of interest,24,25 this study may be more
accurate in representing the general population of anemic
CKD patients in clinical practice. On the other hand, practice
patterns of ESA use may have changed since the time period
included in this study, especially among oncology patients,
with recent studies in the non-VHA setting suggesting a
marked decline in its use since 2007 (ref. 26).
Conclusion
In conclusion, among a large national cohort of patients with
CKD and anemia, treatment with ESAs was associated with a
significantly greater risk of acute stroke, and this association
was especially notable among those patients with cancer.
Further studies are needed to examine the mechanisms by
which ESA use may contribute to an increased risk of stroke,
and whether change in the approach to dosing of ESAs may
modify this risk.
MATERIALS AND METHODS
This was a nested, matched case–control study using adminis-
trative data collected by the VHA. This analysis was approved
by the University of Maryland Institutional Review Board and
the VA Maryland Healthcare System Research & Development
Committee.
Data sources
Patient treatment file; the outpatient care file; the decision support
system laboratory result files, which contains results for selected
laboratory tests; the decision support system laboratory ordering files;
the vital status file; and the pharmacy benefits management dataset.
Study sample
Subjects were VHA patients with an initial outpatient eGFR
o60 cm3/min per 1.73 m2 during one of three time periods
from 2000 to 2005 (1 April 2000 to 31 March 2001; 1 April 2002
to 31 March 2003; or 1 April 2004 to 31 March 2005) and a
subsequent outpatient Hb o12 g/dl. eGFR was estimated from
outpatient serum creatinine concentration using the four-variable
Modification of Diet in Renal Disease formula; the date of first
eGFR o60 cm3/min per 1.73 m2 was termed the ‘incident CKD
date’. The date of the first outpatient Hb o12 g/dl on or after the
index CKD date was considered the ‘index anemia date.’
Case definition
Among patients who met the eGFR and Hb criteria, we identified all
those with an acute-care hospitalization for an acute stroke between
the index anemia date and the last date of follow-up (defined as the
first of death, loss to follow-up, or 9/30/2005 (the last date of data
available in the data set)); these patients were defined as stroke cases.
Acute stroke was ascertained using an International Classification of
Diseases (9th revision) discharge diagnosis coding algorithm that
has been validated as highly accurate for the ascertainment of actual
stroke cases, and included both ischemic and hemorrhagic strokes.23
Controls were selected among those patients who did not experience
an acute stroke hospitalization between the index anemia date and
end of follow-up. Each case was matched to five control patients
based on the patients’ total duration of observation after incident
anemia (±60 days). The date of acute stroke (for cases) or
equivalent date of follow-up without an acute stroke (for controls)
was termed the ‘study index date’.
Exposures and covariates
The primary exposure of interest was ESA treatment prior to the
study index date, including both darbepoetin alfa and epoetin alfa.
Patients with evidence of X1 filled outpatient ESA prescriptions
before the study index date were considered as having been treated
with ESAs. The mean weekly dose from the initial ESA prescription
was also determined. ESA-treated patients were divided into high-
dose and low-dose groups using the median initial dose of each ESA
drug, with those patients (29%) receiving the exact median dose
assigned to the high-dose group.
Patient characteristics that might relate to stroke and ESA use
were abstracted and considered as potential adjustment covariates.
These characteristics included: demographics (age, race, ethnicity),
comorbidity defined by inpatient and/or outpatient diagnosis codes
(diabetes, cancer (excluding non-melanoma skin cancer) with
concurrent active oncology care, hypertension, CAD, prior myo-
cardial infarction, prior TIA, gastrointestinal bleed, prior stroke,
atrial fibrillation), healthcare utilization (prior outpatient care in
cardiology, nephrology, hematology/oncology, or chemotherapy
clinics), acute-care inpatient hospitalizations, and laboratory results
(outpatient eGFR and Hb). To define comorbidity, prior healthcare
utilization, renal function, and severity of anemia, we used records
occurring before the initiation of ESA use (for those prescribed
ESAs; see below) or before the study index date (for those not using
ESAs).
Statistical analysis
Patient characteristics were compared between stroke cases and
controls using w2 tests and t-tests for categorical and continuous
variables, respectively. Conditional logistic regression, as appropriate
for the case–control study design, was used to estimate the
association of ESA use with stroke case status, while controlling
for potential confounders. A hierarchical modeling approach was
used, adjusting for sets of progressively more complete confounders.
In the primary analysis, ESA use was considered as a binary variable
(treated/untreated). In secondary analyses, we examined dose–
response relations by comparing those with initial high and low
doses with untreated patients. We tested for interaction between
ESA use and diabetes, cancer under active oncologic care, prior
cerebrovascular disease (TIA and/or stroke), atrial fibrillation, CAD,
and recent nephrology care (within prior 6 months) using
multiplicative interaction terms.
As significant interactions were noted between ESA use and the
presence of cancer, we further compared differences in age, median
first dose, and pre-ESA eGFR and Hb. To examine the response of
Hb to ESA initiation, separate patient-specific linear regression
models were developed to estimate the individual slope of Hb versus
time in the 6 months following ESA initiation, truncating measures
at 30 days after end of the last ESA prescription within this 6-month
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period. Separate analyses were performed for patients who used
darbepoetin alfa and those who used epoetin alfa.
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